Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
877 Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression
Compose a Response to This Article
Other responses
No responses have been published for this article.